Heska's Hematology Analyzer Selected by VetSmart as

Equipment of Choice FORT COLLINS, Colo. (PROTEXT) - Heska Corporation (Nasdaq: HSKA), today announced that VetSmart Pet Hospitals and Health Centers, a leading provider of veterinary services, has selected the HESKA(TM) Vet ABC-Diff Hematology Analyzer as the hematology analyzer of choice for use in its veterinary hospitals and wellness clinics. The Vet ABC-Diff Hematology Analyzer is a convenient and easy- to-use tabletop blood cell counter which provides crucial clinical information to the veterinarian in less than two minutes. This information includes the results of 16 different blood parameters with the accuracy of more expensive reference laboratory equipment. Heska is the exclusive North American distributor for the Vet ABC-Diff unit, which is provided by Scil GmbH, a former subsidiary of Boehringer Mannheim GmbH. The diagnostic instrument's potential has been recognized by one of the largest multiple-location veterinary practices in the world. "VetSmart's focus on high quality, convenient and affordable medicine has enabled us to grow to over 385 locations in 37 states throughout the country," said Scott Campbell, DVM and Don Spear, Senior Partners at VetSmart. "When making an investment of this magnitude, we considered every hematology analyzer on the market today. We chose Heska's Vet ABC-Diff unit because it was the best unit to give our partner doctors a valuable tool to continue treating pets like family. We believe Heska is also uniquely qualified to supply us with the after- sales service and technical consultation to continually keep our hospitals on the leading edge of hematology practice." Jim Fuller, President and Chief Operating Officer of Heska Corporation, said, "We are especially pleased with VetSmart's decision to adopt our Vet ABC-Diff unit as their hematology instrument of choice. We believe this represents the start of a long-term relationship with VetSmart and demonstrates their strong support of our company and our products." Heska discovers, develops, manufactures and markets companion animal health products, primarily for dogs, cats and horses. Heska has a large and sophisticated scientific effort devoted to applying biotechnology to the large and growing companion animal health market. Heska also offers diagnostic and patient monitoring equipment and supplies, as well as laboratory diagnostic products in the United States and Europe to veterinarians, and operates USDA- and FDA-licensed facilities which manufacture vaccine, pharmaceutical, and allergy immunotherapy products. For additional information on Heska and its products, visit the company's web site at www.heska.com. Except for the historical information contained herein, the matters set forth in this press release, such as statements as to market acceptance of Heska's products and services, and the relationship with VetSmart are forward- looking statements that are subject to risks and uncertainties. Such forward- looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Heska to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Heska's achievement of these results may be affected by many factors, including among others, the following: delays in or failure to achieve market acceptance of products; delays in or failure to achieve future product development; uncertainties regarding the outcome of research and development efforts or the ability to successfully develop or commercialize products in research and development, uncertainties regarding the ability to receive required regulatory approvals in a timely manner, if at all, uncertainties regarding the scope, enforceability and validity of patents and proprietary rights; competition; inability to obtain renewal or continuation of contracts, or obtain exclusivity, to market, sell or distribute products described herein; inability to manufacture, market, sell or distribute products at currently projected costs and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended March 31, 1999. ots Original Text Service: Heska Corporation Internet: http://www.newsaktuell.de Contact: Ron Hendrick, Executive Vice President & Chief Financial Officer of Heska Corporation, 970- 493-7272, ext. 4105; or Matthew Knight, 212-696-4455 ext. 271 (Media), or Ana Kapor, 415-677-4455 ext. 207, both of Noonan/Russo Communications Inc. for Heska Corporation Web site: http://www.heska.com Subscribers please note that material bearing the slug "PROTEXT" is not part of CTK's news service and is not to be published under the "CTK" slug. Protext is a commercial service providing distribution of press releases from clients, who are identified in the text of Protext reports and who bear full responsibility for their contents. PROTEXT